BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 57.45M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 57.45M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 57.45M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 57.45M | (m) | (m) |
| 2026-03-31 | 57.30M | (m) | (m) |
| 2025-12-31 | 57.29M | (m) | (m) |
| 2025-09-30 | 56.97M | (m) | (m) |
| 2025-06-30 | 56.94M | (m) | (m) |
| 2025-03-31 | 56.86M | (m) | (m) |
| 2024-12-31 | 56.66M | (m) | (m) |
| 2024-09-30 | 56.59M | (m) | (m) |
| 2024-06-30 | 56.50M | (m) | (m) |
| 2024-03-31 | 56.25M | (m) | (m) |
| 2023-12-31 | 51.72M | (m) | (m) |
| 2023-09-30 | 51.64M | (m) | (m) |
| 2023-06-30 | 51.58M | (m) | (m) |
| 2023-03-31 | 36.51M | (m) | (m) |
| 2022-12-31 | 36.48M | (m) | (m) |
| 2022-09-30 | 36.37M | (m) | (m) |
| 2022-06-30 | 36.34M | (m) | (m) |
| 2022-03-31 | 36.29M | (m) | (m) |
| 2021-12-31 | 36.27M | (m) | (m) |
| 2021-09-30 | 36.23M | (m) | (m) |
| 2021-06-30 | 36.21M | (m) | (m) |
| 2021-03-31 | 36.16M | (m) | (m) |
| 2020-12-31 | 36.14M | (m) | (m) |
| 2020-09-30 | 36.00M | (m) | (m) |
| 2020-06-30 | 35.91M | (m) | (m) |
| 2020-03-31 | 35.91M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |